Popular Articles From: European Commission Approves Huntsman's Acquisition Of Rockwood's Performance Additives And Titanium Dioxide Businesses to Inland Real Estate Corporation Pays September and Declares October Cash Distribution to Common Stockholders


Huron Consulting Group (NASDAQ: HURN), a leading provider of business consulting services, today announced that it has been named a Top Workplace by The Oregonian for the second consecutive year.
Sign-up for Huron Consulting Group Named a 2014 Top Workplace by The Oregonian investment picks
Huron Consulting Group Inc. (NASDAQ:HURN), a leading provider of business consulting services, today announced the pricing of $225 million aggregate principal amount of convertible senior notes due 2019 (the "Convertible Notes"). The Convertible Notes were offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company granted an option to the initial purchasers to purchase, within a period of 13 days beginning on, and including, the date the Convertible Notes are first issued, up to an additional $25 million aggregate principal amount of Convertible Notes.
Sign-up for Huron Consulting Group Prices Private Offering of $225 Million of Convertible Senior Notes Due 2019 investment picks
BRISBANE, Calif., June 25, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the European Medicines Agency (EMA) has completed technical and content validation and accepted the filing of the Marketing Authorisation Application (MAA) for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs). Acceptance of the MAA confirms that the submission is complete so as to permit a substantive review by the Rapporteurs and the Committee for Medicinal Products for Human Use (CHMP). "We are very pleased to receive MAA acceptance for review of RAVICTI and anticipate a CHMP opinion in the third quarter of 2015," said Donald J.
Sign-up for Hyperion Therapeutics Announces EMA Acceptance for Review of Marketing Authorization Application for RAVICTI(R) investment picks
First Watson Consumer Facing Application Available to USAA Members ARMONK , N.Y. and SAN ANTONIO , July 23, 2014 /PRNewswire/ -- IBM (NYSE: IBM ) and USAA announced that the cognitive capabilities of IBM Watson technology are now available to USAA members.
Sign-up for USAA and IBM Join Forces to Serve Military Members investment picks
New chip with brain-inspired non-von Neumann computer architecture has one million neurons and 256 million synapses Built on Samsung's 28nm process technology, the 5.4 billion transistors chip has an on-chip network of 4096 neurosynaptic cores but only consumes 70mW during real-time operation Complete cognitive hardware and software ecosystem opens new computing frontier for mobile, cloud, supercomputing and distributed sensor applications SAN JOSE, Calif.
Sign-up for New IBM SyNAPSE Chip Could Open Era of Vast Neural Networks investment picks
The beginning of a transition from e-Government to m-Government ZAGREB, Croatia , Sept.
Sign-up for Croatia Builds New Mobile Government on IBM Mainframe - citizens can now access critical services in just minutes investment picks
Fast-growing bank inks 5-year deal with IBM for IT management services in West Africa ACCRA, Ghana and WASHINGTON , Aug.
Sign-up for At U.S. - Africa Business Forum, Ghana's Fidelity Bank Chooses IBM to Drive Transformation Agenda investment picks
New cloud-based service delivers near-real time HD content to global sports fans ARMONK, N.Y. , Sept.
Sign-up for Aspera, an IBM Company, Partners with EVS and Elemental to Bring Unprecedented Second Screen Video Streaming to Millions of Sports Fans Worldwide investment picks
Actua to Trade on the NASDAQ Under Ticker Symbol ACTA RADNOR, Pa., Sept.
Sign-up for ICG Changes Name to Actua, Reflecting Evolution to a Multi-Vertical Cloud Company investment picks
By Jennifer Booton, MarketWatch NEW YORK (MarketWatch) -- Jennifer Lawrence's bottom might be blasted out for the world to see, but don't expect people to shy away from cloud computing or Apple products in general.
Sign-up for Celeb nude photos won't hurt the cloud investment picks
RALEIGH, N.C., Aug.
Sign-up for Icon Media Holdings, Inc. Opens MMJ-X.COM for Beta investment picks
BOISE, Idaho , Sept.
Sign-up for IDACORP Increases Quarterly Common Stock Dividend 9.3 Percent investment picks
http://media.marketwire.com/attachments/201311/207012_jpg_IPC_Logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1143512&ProfileId=051205&sourceType=1 AUSTIN, TX --
Sign-up for Ideal Power Appoints Industry Veteran Ryan O'Keefe as Senior Vice President, Business Development investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today reported financial and operational results for the quarter ended June 30, 2014.
Sign-up for Idera Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Corporate Update investment picks
WINDERMERE, Fla.
Sign-up for iMedicor Signs Relationship with Florence-Darlington Technical College investment picks
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today the closing of its initial public offering of 5,000,000 shares, at a public offering price of $12.00 per share, resulting in aggregate gross proceeds of $60.0 million, before underwriting discounts, commissions and expenses.
Sign-up for Immune Design Announces Closing of Initial Public Offering investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0961044001&sourceType=1 http://media3.marketwire.com/logos/20121102-iiinew.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Imperial Update on Tailings Storage Facility Breach at Mount Polley Mine investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0966234001&sourceType=1 http://media3.marketwire.com/logos/20121102-iiinew.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Imperial Completes $115 Million Non-Brokered Private Placement of Convertible Debentures investment picks
WILMINGTON, Mass.
Sign-up for Implant Sciences Responds to Levi & Korsinsky, LLP Press Release /Solicitation investment picks
Luxoft Holding, Inc (NYSE:LXFT), a leading provider of software development services and innovative IT solutions to a global client base, today announced that IBS Group Holding Limited (“IBS Group”), the controlling shareholder of Luxoft Holding, Inc (“Luxoft” or the “Company”) announced its intent to propose a reorganization of IBS Group via an exchange of shares and Global Depository Receipts (“GDRs”) in IBS Group for shares of Luxoft through a scheme of arrangement (the “Scheme”). According to IBS Group’s announcement, pursuant to the proposed Scheme, global depositary receipts of IBS Group and issued and outstanding shares of IBS Group, other than the shares held by BXA Investments Ltd (“BXA”) and Croyton Limited (“Croyton”), (together, the “Scheme Securities”) will be cancelled and class B shares of the Company will be transferred to the holders of the Scheme Securities in
Sign-up for Luxoft Holding Announces a Proposed Reorganization of its Majority Shareholder, IBS Group Holding, Involving an Exchange of a Portion of IBS Group's Share Capital for a Portion of its Shares in Luxoft investment picks
Schubert Jonckheer & Kolbe LLP Investigates Case Against the Company's Top Executives SAN FRANCISCO , Sep.
Sign-up for ESI Shareholder Alert: Do You Own Stock in ITT Educational Services? investment picks
Advisory services team reimagines the branch experience for downtown Albany, N.Y., location NORTH CANTON, Ohio , Sept.
Sign-up for Diebold Guides Branch Transformation Journey For Kinderhook investment picks
Incyte Corporation (Nasdaq: INCY) today reported 2014 second-quarter financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company highlighted its strong financial position, driven by growing Jakafi sales in the U.S. and Jakavi ® (ruxolitinib) royalties outside the U.S., as well as the submission of the ruxolitinib supplemental New Drug Application (sNDA) in the U.S. for patients with uncontrolled polycythemia vera (PV). The Company also discussed its expanding clinical pipeline, which includes pivotal as well as proof of concept studies, and the multiple data presentations for the Company’s product candidates that were made at the recent American Society of Clinical Oncology (ASCO) meeting.
Sign-up for Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs investment picks
Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food & Drug Administration (FDA) has approved supplemental labeling for Jakafi ® (ruxolitinib) to include new Kaplan-Meier overall survival curves as well as additional safety and dosing information.
Sign-up for Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information investment picks
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the BMO Capital Markets 3 rd Annual Biotech Corporate Access Day on July 29, 2014.
Sign-up for Infinity to Participate in the BMO Capital Markets 3RD Annual Biotech Corporate Access Day investment picks
SAN DIEGO , Sept.
Sign-up for InfoSonics Reveals Its First LTE Smartphone: the verykool® SL5000 'Quantum' investment picks
Inland Real Estate Corporation (NYSE: IRC) today announced that it paid a cash distribution of $0.0475 per share on the outstanding shares of its common stock to common stockholders of record at the close of business on September 2, 2014.
Sign-up for Inland Real Estate Corporation Pays September and Declares October Cash Distribution to Common Stockholders investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Popular Articles From: European Commission Approves Huntsman's Acquisition Of Rockwood's Performance Additives And Titanium Dioxide Businesses to Inland Real Estate Corporation Pays September and Declares October Cash Distribution to Common Stockholders
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices